ResearcherShinshu UniversityActive in the last 2 years

Satoru Miyazaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8803-7980; OpenAlex author ID A5006530930, A5017921849. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: 1 paper

Papers 2

Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2. Co-author DOI 10.1002/1878-0261.13751 ↗
Increased mitochondria are responsible for the acquisition of gemcitabine resistance in pancreatic cancer cell lines. Co-author DOI 10.1111/cas.15962 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yuji Soejima · 2 shared papers, 2023–2025 · strength 0.42
- Paper Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2. DOI 10.1002/1878-0261.13751 ↗
- Paper Increased mitochondria are responsible for the acquisition of gemcitabine resistance in pancreatic cancer cell lines. DOI 10.1111/cas.15962 ↗
Kôji Kubota · 1 shared paper, 2023 · strength 0.18
- Paper Increased mitochondria are responsible for the acquisition of gemcitabine resistance in pancreatic cancer cell lines. DOI 10.1111/cas.15962 ↗
Hitoshi Masuo · 1 shared paper, 2023 · strength 0.18
- Paper Increased mitochondria are responsible for the acquisition of gemcitabine resistance in pancreatic cancer cell lines. DOI 10.1111/cas.15962 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.